子分类：
| 序号 | 专利名 | 申请号 | 申请日 | 公开（公告）号 | 公开（公告）日 | 发明人 |
|---|---|---|---|---|---|---|
| 61 | Process for the preparation of dispersions of cross-linking agents in water | US12278275 | 2007-01-10 | US08969471B2 | 2015-03-03 | Laurentius Cornelis Josephus Hesselmans; Marthe Hesselmans; Andries Johannes Derksen |
| A process for the preparation of stable aqueous polycarbodiimide dispersions to be used as cross-linking agents, in which initially an isocyanate functional polycarbodiimide is prepared from a polyisocyanate and a mono- or polyisocyanate which contains a hydrophobic group. Thereafter the polycarbodiimide chain is capped and/or extended by reaction of the isocyanate functions or a part thereof with a hydrophilic amine- or hydroxy functional compound and of the remaining isocyanate functions with an amine- or hydroxy functional compound which contains hydrophobic groups, after which the obtained product is dispersed in water and the pH is adjusted to 9-14. The hydrophobic groups are hydrocarbons with 4-25 carbon atoms, fluorinated hydrocarbons, silicone functional hydrocarbons or polysilicones. Further, the invention relates to a coating mixture in which the polycarbodiimide dispersion is used as cross-linking agent and to the cured material obtained with the coating mixture. | ||||||
| 62 | Amino acid derivatives used as pharmaceutical substances | US12847544 | 2010-07-30 | US08658826B2 | 2014-02-25 | Bernd Clement; Christiane Wolter-Reeh; Helen Schenk |
| The invention relates to a method for improving bioavailability of pharmaceutical substances and for allowing the pharmaceutical substances to permeate the blood-brain barrier, the pharmaceutical substances having at least one or more amidine, guanidine, N-hydroxyamidine (amidoxime) or N-hydroxyguanidine functions. The invention also relates to medicaments containing the correspondingly modified pharmaceutical substances. | ||||||
| 63 | S1P3 receptor antagonist | US12088861 | 2006-10-11 | US08546452B2 | 2013-10-01 | Shin-ya Ohnuma; Takeshi Hasegawa; Tomoyuki Sada |
| The present invention relates to arylamidrazone derivatives having an antagonistic action against S1P3 receptors represented by the following formula (1) or a pharmaceutically acceptable salt thereof: | ||||||
| 64 | Method for producing colorless isocyanurates of diisocyanates | US12530469 | 2008-03-27 | US08373004B2 | 2013-02-12 | Harald Schaefer; Carl Jokisch; Horst Binder; Matthias Kroner; Alexander Bayer |
| The present invention relates to a novel process for preparing colorless, isocyanurate group-comprising polyisocyanates of (cyclo)aliphatic diisocyanates. | ||||||
| 65 | Substituted phenylamidines and the use thereof as fungicides | US12530566 | 2008-03-08 | US08334237B2 | 2012-12-18 | Thomas Seitz; Klaus Kunz; Wahed Ahmed Moradi; Jörg Nico Greul; Darren James Mansfield; Urlich Heinemann; Amos Mattes; Oswald Ort; Jean-Pierre Vors; Peter Dahem; Ulrike Wachendorff-Neumann; Arnd Voerste |
| The present invention relates to oxime ether-, hydrazone- or azomethine-substituted phenylamidines of the general formula (I), to a process for their preparation, to the use of the amidines according to the invention for controlling unwanted microorganisms and also to a composition for this purpose, comprising the amidines according to the invention. Furthermore, the invention relates to a method for controlling unwanted microorganisms by applying the compounds according to the invention to the microorganisms and/or their habitat. | ||||||
| 66 | PROCESS 738 | US13264217 | 2010-04-22 | US20120108814A1 | 2012-05-03 | Kay Alison Boardman; Oliver Robert Cunningham; William Robert Fraser Goundry; David Dermot Patrick Laffan |
| Processes for the preparation of 4-(3-chloro-2-fluoroanilino)-7-methoxy-6-{[1-(N-methylcarbamoylmethyl)piperidin-4-yl]oxy}quinazoline, salts thereof, and the intermediates used in the process are described. | ||||||
| 67 | Iminium salts and methods of preparing electron deficient olefins using such novel iminium salts | US12424198 | 2009-04-15 | US08022251B2 | 2011-09-20 | Ciaran B. McArdle; Ligang Zhao |
| This invention relates to novel iminium salts, which may be in the form of ionic liquids, and a process for producing electron deficient olefins, such as 2-cyanoacrylates, using such an iminium salt, for instance in the form of an ionic liquid. | ||||||
| 68 | ACETYL MIMIC COMPOUNDS FOR THE INHIBITION OF ISOPRENYL-S-CYSTEINYL METHYLTRANSFERASE | US12867796 | 2009-02-13 | US20110053901A1 | 2011-03-03 | Seung-Yub Lee; Michael Voronkov; Peter Wolanin |
| Among other things, the present invention provides novel compounds capable of effectively inhibiting inflammatory responses that are mediated by G-proteins or GPCRs in neutrophils, macrophages and platelets. In particular, compounds of the present invention act as inhibitors of edema, inhibitors of erythema and inhibitors of MPO (myeloperoxidase), pharmaceutical compositions containing the same compounds and the use thereof for the treatment of diseases that may benefit from edema, erythema and MPO inhibition, such as inflammation (acute or chronic), asthma, autoimmune diseases, and chronic obstructive pulmonary disease (COPD) (e.g., emphysema, chronic bronchitis and small airways disease, etc.), inflammatory responses of the immune system, skin diseases (e.g., reducing acute skin irritation for patients suffering from rosacea, atopic dermatitis, seborrheic dermatitis, psoriasis), irritable bowel syndrome (e.g., Chron's disease and ulcerative colitis, etc.), and central nervous system disorders (e.g., Parkinson's disease). | ||||||
| 69 | Phenylazo-acetoacetanilide derivatives with a polymerizable functional group and related compounds as monomers for preparing polymeric pigment dispersants for inkjet inks | US11995329 | 2006-07-04 | US07812113B2 | 2010-10-12 | Geert Deroover; Wojciech Jaunky; Lambertus Groenendaal; Johan Loccufier |
| A monomer with a chromophore group represented by Formula (I): wherein AR1 represents a substituted or unsubstituted aromatic group; AR2 represents a substituted or unsubstituted aromatic group or a substituted or unsubstituted alkyl group; and R represents a substituted or unsubstituted alkyl group, with the proviso that one of R, AR1, and AR2 has a substituent with a polymerizable functional group. The monomer can be advantageously used to prepare polymeric dispersants for pigment dispersion, especially inkjet inks. | ||||||
| 70 | BIARYL AND BIHETEROARYL COMPOUNDS USEFUL IN TREATING IRON DISORDERS | US12051741 | 2008-03-19 | US20080234384A1 | 2008-09-25 | Mikhail Chafeev; Nagasree Chakka; Jean-Jacques Cadieux; Jianmin Fu; Rajender Kamboj; Vishnumurthy Kodumuru; Jonathan Langille; Shifeng Liu; Jianyu Sun; Serguei Sviridov; Zaihui Zhang |
| This invention is directed to compounds of formula (I): wherein m, n, R1, R2 and R3 are as defined herein, as a stereoisomer, enantiomer, tautomer thereof or mixtures thereof; or a pharmaceutically acceptable salt, solvate or prodrug thereof, for the treatment of iron disorders. This invention is also directed to pharmaceutical compositions comprising the compounds and methods of using the compounds to treat iron disorders. | ||||||
| 71 | Fermentation and purification of migrastatin and analog | US10838895 | 2004-05-03 | US07375230B2 | 2008-05-20 | Chaitan Khosla; Peter J. Licari; John R. Carney |
| Migrastatin and a migrastatin analog can be produced by fermentation of Streptomyces platensis NRRL 18993 and used in pharmaceutical formulations to treat cancer and/or inhibit metastasis of cancer cells. | ||||||
| 72 | Multistage continuous preparation of cycloaliphatic diisocyanates | US11185776 | 2005-07-21 | US07371891B2 | 2008-05-13 | Stephan Kohlstruk; Manfred Kreczinski; Hans-Werner Michalczak |
| The invention relates to a multistage process for continuous and phosgene-free preparation of cycloaliphatic diisocyanates. | ||||||
| 73 | Bisaminophenyl-based curatives and amidine-based curatives and cure accelerators for perfluoroelastomeric compositions | US10768839 | 2004-01-29 | US20050020859A1 | 2005-01-27 | Carl Aufdermarsh; Harshad Amin; Anestis Logothetis; Victor Gubanov; Margarita Volkova; Lioudmila Karmanova; Alexandr Kollar; Polina Troichanskaia; Gennady Emelianov; Vsevolod Berenblit |
| Novel monoamidine, monoamidoxime and bisamidine curatives, co-curatives and cure accelerators are provided for use with perfluoroelastomeric compositions as well as novel synthesis methods for making monoamidine- and monoamidoxime-based curatives, co-curatives and cure accelerators. Also provided are diphenyl-based curatives, co-curatives and cure accelerators having sufficiently high molecular weight such that the melting temperature of the curatives, co-curatives and cure accelerators is no greater than about 240° C., and more preferably no greater than about 230° C. | ||||||
| 74 | Amidine derivatives with nitric oxide synthetase activities | US111926 | 1998-07-08 | US6030985A | 2000-02-29 | Robert James Gentile; Robert John Murray; James Edwin MacDonald; William Calvin Shakespeare |
| The present invention relates to methods and compositions useful for treating and preventing conditions in which inhibition of nitric oxide synthetase is beneficial. These conditions include stroke, schizophrenia, anxiety, and pain. | ||||||
| 75 | Method of thrombin inhibition | US481811 | 1995-06-07 | US5939392A | 1999-08-17 | Karl Thomas Antonsson; Ruth Elvy Bylund; Nils David Gustafsson; Nils Olov Ingemar Nilsson |
| The invention relates to new competitive tripeptide inhibitors of trypsin-like serine proteases, their synthesis, pharmaceutical compositions containing the compounds as active ingredients, and the use of the compounds as thrombin inhibitors, anticoagulants and antiinflammatory inhibitors for prophylaxis and treatment of related diseases. | ||||||
| 76 | Amidine derivatives with nitric oxide synthetase activities | US586761 | 1996-01-30 | US5807885A | 1998-09-15 | Robert James Gentile; Robert John Murray; James Edwin MacDonald; William Calvin Shakespeare |
| Amidine derivative compounds of formula I as defined in the Specification having nitric oxide synthetase inhibitory activity as well as processes for the preparation of and compositions containing said compounds are described. | ||||||
| 77 | Polyisocyanate compositions having a long shelf life and obtainable by phosgene-free methods, their preparation and their use | US647877 | 1996-05-13 | US5728317A | 1998-03-17 | Gerhard Laqua; Franz Merger; Tom Witzel; Ursula Siebenhaar; David Agar |
| (Cyclo)aliphatic polyisocyanate compositions which have a long shelf life, are obtainable by phosgene-free methods, preferably by thermal cleavage of (cyclo)aliphatic polycarbamates, and, for stabilization, contain at least one primary stabilizer (2a), preferably a sterically hindered phenol and/or an aromatic amine, or at least one secondary stabilizer (2b), preferably an organic phosphite and/or a thioether, or at least one acidic stabilizer (2c), preferably a carboxylic acid, an acyl chloride, an inorganic acid, an inorganic acid chloride and/or a diester of phosphoric acid, or a stabilizer system comprising at least 2 of the stabilizers (2a) to (2c), a process for the preparation of the (cyclo)aliphatic polyisocyanate compositions and their preferred use for the preparation of isocyanurate-containing polyisocyanates. | ||||||
| 78 | Peptides derivatives | US468046 | 1995-06-06 | US5602253A | 1997-02-11 | Karl T. Antonsson; Ruth E. Bylund; Nils O. I. Nilsson |
| The invention concerns the compound of the formula: ##STR1## and protected forms and salts thereof which serve as starting materials in an improved method of synthesizing serine protease inhibitors. The invention further concerns an improved method for synthesizing serine protease inhibitors which utilizes the compounds. | ||||||
| 79 | 이노시톨 또는 트리할로스 유도체 및 이를 함유하는 퇴행성뇌신경계 질환 치료용 약학 조성물 | KR1020080071383 | 2008-07-22 | KR1020100010418A | 2010-02-01 | 정성기; 이우설; 김보람; 임정균; 서브해쉬씨.고쉬 |
| PURPOSE: An inositol or trehalos derivative is provided to facilitate the transmission of a brain nerves system due to high permeability for a blood-brain barrier, and to be used for the treatment of neurodegenerative diseases such as Alzheimer disease or Huntington disease. CONSTITUTION: An inositol or its salt has a structure represented by chemical formula 1 or 2. In chemical formula 1, R1 is hydrogen, R, alkyl or -COR, wherein R' is hydrogen, alkyl, aminoalkyl, aryl alkyl, cycloalkyl or heteroalkyl; R is functional groups of chemical formula 1-a or chemical formula 1-b, wherein n is an integer of 1-12. In chemical formula 2, R1 and R2 are independently hydrogen, alkyl or -COR', wherein R' is hydrogen, alkyl, aminoalkyl, arylalkyl, cycloalkyl or heteroalkyl. | ||||||
| 80 | 1-아릴-5-(트리플루오로메틸)-1Ｈ-테트라졸의 제조 방법 | KR1020077015862 | 2004-09-30 | KR100794282B1 | 2008-01-11 | 하기야가즈타케; 사토야스히로; 고구로기요토; 미츠이스나오 |
| 본 발명은, 화학식 1로 표기되는 2,2,2-트리플루오로-N-아릴-아세트이미드와, 옥시염화인 및 디페닐인산 클로라이드로 이루어진 군으로부터 선택된 적어도 1종과, 제삼급 아민을, 유기용매 중에서 반응시키는, 화학식 2로 표기되는 N-아릴-2,2,2-트리플루오로아세트이미도일 클로라이드의 제조방법에 관한 것이다. 또한 본 발명은, 화학식 2로 표기되는 N-아릴-2,2,2-트리플루오로아세트이미도일 클로라이드와 아지드화물을, 아민염의 존재하에서 방향족 탄화수소 용매 중에서 반응시키는, 화학식 4로 표기되는 1-아릴-5-(트리플루오로메틸)-1H-테트라졸의 제조방법에 관한 것이다. (1) (2) (4) N-아릴-2,2,2-트리플루오로아세트이미도일 클로라이드, 1-아릴-5-(트리플루오로메틸)-1H-테트라졸 | ||||||
QQ群二维码
意见反馈
意见反馈